Published in
Nature Research, Nature Medicine, 11(19), p. 1469-1472, 2013
DOI: 10.1038/nm.3352
Links
- ORCID
- Nature Research | PDF
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer
,
Anh T. Le,
Severine Kako,
Mohit Butaney ,
Dalia Ercan,
Sakshi Mahale,
Kurtis D. Davies,
Dara L. Aisner,
Amanda B. Pilling,
Eamon M. Berge,
Jhingook Kim,
Hidefumi Sasaki,
Seung-Il Park,
Gregory Kryukov
and other authors.
Full text: Download
Abstract
We identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor (TRKA protein). Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth. Tumor samples from 3 of 91 patients with lung cancer (3.3%) without known oncogenic alterations assayed by next-generation sequencing or fluorescence in situ hybridization demonstrated evidence of NTRK1 gene fusions.